Polycystic ovary syndrome. Polycystic ovarian syndrome
Conditions
Interventions
Intervention 1: Intervention group: 500 mg spirulina oral capsule (Khalije Fars Biotechnology Development Company, Tehran-Iran), twice a day, for 12 weeks. Intervention 2: Control group: Placebo oral
Sponsors
Kashan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
25 Years to 40 Years
Inclusion criteria
Inclusion criteria: Patients with polycystic ovary syndrome according to Rotterdam criteria Women aged 25-40 years Complete informed consent
Exclusion criteria
Exclusion criteria: Hyperprolactinemia Thyroid disorders Subjects following a special diet or consuming drugs with an effect on hormonal profile like oral conceptives (OCP) Steroid hormones, or any other drugs probably to affect ovarian action in the last 3 months Type 2 diabetes mellitus (T2DM) Cushing’s syndrome Smokers Unwillingness to cooperate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Clinical symptoms. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire PCOS (Based on NIH criteria). | — |
Secondary
| Measure | Time frame |
|---|---|
| Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactElahe Heydarianfard
Kashan University of Medical Sciences
Outcome results
None listed